Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404679 | 0.83 | RAB9A (0.51) | DRD2DRD3ALDH1A1LMNADDB1 | |
| SCHEMBL6399679 | 0.83 | DRD2 (0.43) | DRD2DRD3CTSGCMA1ALOX5 | |
| SCHEMBL6399716 | 0.82 | MEN1 (0.59) | DRD2DRD3CTSGCMA1ALOX5 | |
| SCHEMBL6401082 | 0.82 | DRD2 (0.47) | DRD2DRD3CTSGCMA1ALOX5 | |
| SCHEMBL9819344 | 0.81 | DRD2 (0.48) | DRD2DRD3CTSGCMA1ALOX5 | |
| SCHEMBL11659061 | 0.77 | DRD2 (0.50) | DRD2DRD3CTSGCMA1ALOX5 | |
| SCHEMBL909211 | 0.74 | DRD2 (0.48) | DRD2DRD3CTSGCMA1ALOX5 | |
| SCHEMBL9819480 | 0.72 | ALB (0.43) | ALOX5ALDH1A1LMNAHSD11B1ALOX15 | |
| SCHEMBL9819315 | 0.72 | MAPT (0.48) | DRD2DRD3CTSGCMA1ALOX5 | |
| SCHEMBL31318721 | 0.71 | ALOX5 (0.43) | CTSGCMA1ALOX5ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | DRD2 1723/4885DRD3 2242/4885CTSG 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.